Investors Buy Large Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the target of unusually large options trading activity on Wednesday. Traders bought 33,531 call options on the stock. This represents an increase of approximately 180% compared to the typical volume of 11,957 call options.

Insiders Place Their Bets

In other news, CFO Michael Secora sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total value of $76,923.84. Following the completion of the transaction, the director now directly owns 7,077,560 shares in the company, valued at $47,561,203.20. This trade represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,894 shares of company stock worth $279,279 over the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals in the third quarter valued at $25,000. Decker Retirement Planning Inc. purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at about $26,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $7.49 on Thursday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $6.86 and a 200 day moving average price of $6.94. Recursion Pharmaceuticals has a 52 week low of $5.60 and a 52 week high of $15.74. The company has a market cap of $2.93 billion, a P/E ratio of -4.90 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. Research analysts predict that Recursion Pharmaceuticals will post -1.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.